Korean J Hematol 2008; 43(4):
Published online December 31, 2008
https://doi.org/10.5045/kjh.2008.43.4.258
© The Korean Society of Hematology
민재웅 황승재 임연정 이영호
한양대학교 의과대학 한양대학교병원 소아청소년과
Deferasirox is a once-daily, oral iron-chelating agent that is now widely available for the treatment of transfusional hemosiderosis. Deferasirox represents a significant advance in the treatment of iron overload, as the availability of an effective oral therapy has the potential to relieve many patients from the burden of frequent parenteral therapy with the previous reference standard iron chelator, deferoxamine. The well-known drug-related adverse events associated with deferasirox include gastrointestinal disturbances, rash, elevations in liver enzyme levels, and mild increases in serum creatinine levels, but acute renal failure is not common. The authors report a case of acute tubulointerstitial nephritis induced by deferasirox following hematopoietic stem cell transplantation for severe aplastic anemia.
Keywords Exjade, Deferasirox, Nephritis, Acute renal failure, Aplastic anemia, Transfusion, Iron, Transplantation, Hematopoietic cell
Korean J Hematol 2008; 43(4): 258-262
Published online December 31, 2008 https://doi.org/10.5045/kjh.2008.43.4.258
Copyright © The Korean Society of Hematology.
민재웅 황승재 임연정 이영호
한양대학교 의과대학 한양대학교병원 소아청소년과
Jae Woong Min, Seung Jae Hwang, Yeon Jung Lim, Young Ho Lee
Department of Pediatrics, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea
Deferasirox is a once-daily, oral iron-chelating agent that is now widely available for the treatment of transfusional hemosiderosis. Deferasirox represents a significant advance in the treatment of iron overload, as the availability of an effective oral therapy has the potential to relieve many patients from the burden of frequent parenteral therapy with the previous reference standard iron chelator, deferoxamine. The well-known drug-related adverse events associated with deferasirox include gastrointestinal disturbances, rash, elevations in liver enzyme levels, and mild increases in serum creatinine levels, but acute renal failure is not common. The authors report a case of acute tubulointerstitial nephritis induced by deferasirox following hematopoietic stem cell transplantation for severe aplastic anemia.
Keywords: Exjade, Deferasirox, Nephritis, Acute renal failure, Aplastic anemia, Transfusion, Iron, Transplantation, Hematopoietic cell
Daehun Kwag, Sung‑Soo Park, Sung‑Eun Lee, Hee‑Je Kim and Jong Wook Lee
Blood Res 2024; 59():Arihant Jain, Aditya Jandial, Thenmozhi Mani, Kamal Kishore, Charanpreet Singh, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Reena Das, Neelam Varma, Subhash Varma and Pankaj Malhotra
Blood Res 2024; 59():Dong Wook Jekarl, Jae Kwon Kim, Jay Ho Han, Howon Lee, Jaeeun Yoo, Jihyang Lim, Yonggoo Kim
Blood Res 2023; 58(S1): S1-S7